|
Optimizing Electroconvulsive Therapy for Depression Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Optimizing Electroconvulsive Therapy for Depression conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Optimizing Electroconvulsive Therapy for Depression Clinical research trials and Optimizing Electroconvulsive Therapy for Depression health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Optimizing Electroconvulsive Therapy for Depression. Optimizing Electroconvulsive Therapy for Depression Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Optimizing Electroconvulsive Therapy for Depression clinical trial. Human subjects often get the best healthcare possible for their Optimizing Electroconvulsive Therapy for Depression condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Optimizing Electroconvulsive Therapy for Depression  Optimizing Electroconvulsive Therapy for Depression
Optimizing Electroconvulsive Therapy for Depression
For Condition: Bipolar Disorder,Depressive Disorder,Depression
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to evaluate electroconvulsive therapy (ECT) administered concurrently with antidepressant medication. This study will also compare two different types of ECT.
Details: This study addresses 2 issues in the optimization of ECT in patients with major depression: whether patients treated with ECT should receive concurrent treatment with antidepressant medications, and the relative efficacy and side effects of high dosage right unilateral (RUL) ECT compared to low dosage bilateral (BL) ECT. This study has 2 phases. In Phase I, patients are randomized to receive nortriptyline, venlafaxine (Effexor), or placebo while they simultaneously receive either high dosage RUL ECT or low dosage BL ECT. Patients have an electrocardiogram (EKG), a chest x-ray, medical and neurological examinations, and blood tests. Memory function is assessed before and after ECT. Whenever feasible, patients are withdrawn from all prior psychotropic medication before the start of ECT. ECT is administered 3 times per week to inpatients and twice a week to outpatients. Patients continue ECT until they are asymptomatic or until there is a plateau in improvement over 2 treatments. Patients who respond to ECT enter Phase II and add lithium to either nortriptyline or venlafaxine within 1-3 days of the last ECT. Clinical and side effect evaluations and blood level determinations are conducted weekly for the first month, every 2 weeks until Week 12, and every 4 weeks for the remaining 12 weeks. Following any indication of relapse, patients are monitored more intensively and are re-evaluated within 1 week. The neurocognitive battery is readministered to all patients at 2 and 6 months after the acute ECT course, regardless of ECT clinical outcome.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Major depressive episode (unipolar or bipolar) - Pre-ECT score of 20 or higher on Hamilton Rating Scale for Depression - Able to withdraw psychotropic drugs (up to 3 mg/day lorazepam allowed) - ECT indicated Exclusion Criteria: - Schizophrenia, schizoaffective disorder, or other psychosis - Amnestic disorder, dementia, or delirium - Pregnancy - Epilepsy - Current alcohol or substance abuse or dependence - CNS disease or brain injury not associated with psychotropic drug exposure - ECT in the past 6 months - Medical contraindication for treatment with either nortriptyline or venlafaxine, including allergy to amitriptyline, nortriptyline, or venlafaxine; narrow angle glaucoma; sinus node disease; bundle branch disease; myocardial infarction; coronary artery bypass or angioplasty; or angina - Type I antiarrhythmic medication - Supine blood pressure >= 170 mmHg systolic or >= 105 mmHg diastolic at 3 readings over 2 days
Total Enrollment: 630
Location and Contact Information:
Overall Study Official:
HaroldSackeim, Study Chair, New York State Psychiatric Institute and Columbia University
Wake Forest University *Recruiting*
Winston Salem, North Carolina, 27103
United States
Recruiting Vaughn McCall 336-716-2911
Western Psychiatric Institute and Clinic *Recruiting*
Pittsburgh, Pennsylvania, 15213
United States
Recruiting Roger Haskett 412-624-6662
New York State Psychiatric Institute at Columbia University *Recruiting*
New York City, New York, 10032
United States
Recruiting Harold Sackeim 212-543-5855
Washington University *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting Keith Isenberg 314-362-1839
Additional Information:
Study ID Numbers: 61609-01A1;
Study Start Date: February 2001
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00045916
Other Depression Studies:
1. Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression
2. Qigong Therapy For Heart Device Patients
3. Progestin (progesterone-like hormones) induced dysphoria (depressed mood, irritability, anxiety)
4. Treatment of Depression After Coronary Bypass Surgery
5. Treatment of Vascular Depression
Related Studies:
Other Depression Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials
Optimizing Electroconvulsive Therapy for Depression
|
|
|
|
|
|
|
|
